Challenge of primary tumor management in patients with stage IV colorectal cancer

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3165-3166

  Chang, George J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; COLORECTAL CANCER; DISEASE SURVEILLANCE; EDITORIAL; FOLLOW UP; HUMAN; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84866537117     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.5743     Document Type: Editorial

References (12)

1. Hapani S, Chu D, Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 10:559-568, 2009
2. Costi R, Mazzeo A, Di Mauro D, et al: Palliative resection of colorectal cancer: Does it prolong survival? Ann Surg Oncol 14:2567-2576, 2007 (Pubitemid 47389576)
3. Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
4. Chang GJ, Agarwal A, Maru DM, et al: Histopathologic responses in primary tumors of patients with colorectal carcinoma after neoadjuvant systemic chemotherapy alone. European Society of Medical Oncology 12th World Congress on Gastrointestinal Cancer, Barcelona, España, June 30-July 3, 2010 (abstr P-0032)
5. Karoui M, Koubaa W, Delbaldo C, et al: Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 15:3440-3446, 2008
6. Schrag D, Weiser MR, Goodman KA, et al: Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol 28:263s, 2010 (suppl 15; abstr 3511)
7. Poultsides GA, Servais EL, Saltz LB, et al: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379-3384, 2009
8. McCahill LE, Yothers G, Sharif S, et al: Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. J Clin Oncol 10.1200/JCO.2012.42.4044
9. Tebbutt NC, Norman AR, Cunningham D, et al: Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52:568-573, 2003 (Pubitemid 36363413)
10. Scheer MG, Sloots CE, van der Wilt GJ, et al: Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829-1835, 2008
11. Temple LK, Hsieh L, Wong WD, et al: Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475-3484, 2004 (Pubitemid 41103653)
12. Karoui M, Roudot-Thoraval F, Mesli F, et al: Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: Results of a multicentric study. Dis Colon Rectum 54:930-938, 2011